Please assess the completion status of the following clinical trial:

Trial Title: Eosinophilic Airway Inflammation and Mepolizumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females age 18 to 50 yrs,~* History of asthma based upon presence of asthma symptoms such as cough, shortness of breath, wheeze or chest tightness,~* positive skin-prick test to a House Dust Mite extract,~* Forced expiratory volume at one second \>70% predicted pre-albuterol, \> 80% predicted post albuterol~* \>12% increase in Forced expiratory volume at one second following inhaled albuterol (180 µg) and/or~* airway responsiveness to methacholine (PC20 \<8mg/ml).~* \> 20% immediate drop in FEV1 following inhaled antigen challenge.~* Safety laboratory assessments within normal ranges (labs to include complete blood count with differential, blood urea nitrogen, creatinine, aspartate aminotransferase, alanine aminotransferase, Prothrombin time, Partial Thromboplastin Time, and platelet count)~* Female subjects of child-bearing potential must have a negative urine pregnancy test (urine HCG) within 48 hours of the methacholine challenge at Visit 2 and agree to use a reliable method of birth control for the duration of the study (reliable methods of birth control can include abstinence, barrier methods, oral contraceptives, injection contraceptives or skin absorption contraceptives).~* In the opinion of the investigator, capable and willing to grant written informed consent and cooperate with study procedures and requirements.~Exclusion Criteria:~* Use of inhaled or systemic corticosteroids or leukotriene inhibitors within 1 month of screening.~* Treatment with Omalizumab (anti-IgE) within 9 months of screening visit~* Concomitant use of any other monoclonal antibody~* Respiratory infection within 4 weeks of study~* Unstable asthma as indicated by self-report of increased symptoms or increased beta-agonist use over the previous 2 weeks.~* Female subjects who are pregnant, nursing or have a pregnancy planned during the course of study~* Current smokers (defined as smoked within the last year) or a former smoker with a history of \>5 pack years.~* Major health problems such as heart disease, type I and II diabetes or lung diseases other than asthma. Decisions regarding this criteria will be based upon the judgment of the investigator.~* Previous malignancy.~* Medication other than for asthma, allergies or contraception and that the investigator feels may interfere with the conduct of study (e.g. monoamine oxidase inhibitors and B-adrenergic antagonists in any form)~* Known history of allergic reaction to previous antibody administration.~* Prior treatment with an anti-interleukin-5 monoclonal antibody,~* Use of an investigational drug within 30 days of entering the study,~* History of noncompliance with medical regimens or subjects who are considered unreliable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Mepolizumab (Type: EXPERIMENTAL): up to 3 monthly doses of 750mg i.v. mepolizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).